| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa48a431ce250933eb0fdd7a1caf3f30 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00 |
| filingDate |
2007-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd5eff4af85efe9fd5174533f2686383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca140065db761f8db084f56b2fff8aac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae349b5a7f5194e64455ce1aa1dbbbad |
| publicationDate |
2007-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2007238636-A |
| titleOfInvention |
New formulation for transdermal release of pergolide |
| abstract |
The present invention provides a novel formulation for safe and effective transdermal administration of pergolide for the treatment of Parkinson's disease. A composition for releasing pergolide through a body surface or membrane at a therapeutically effective rate to an individual in need of pergolide treatment by permeation through the body surface or membrane for obtaining therapeutic plasma levels of pergolide And a composition containing in the carrier an amount of pergolide mesylate effective to allow sustained release of pergolide with a flow rate of at least 1 μg / cm 2 · hr over the administration period. [Selection] Figure 5 |
| priorityDate |
1995-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |